PDE5A and pulmonary arterial hypertension: Both on demand and chronic use of PDE5 inhibitors to treat erectile dysfunction or pulmonary hypertension, that lead to the increase of intracellular cGMP levels, has raised potential safety issues for the rupture of pre-existing aneurysms41.